Cialis Side Effects: Incidence Rates Across Clinical Trials

What the FDA Prescribing Label Says About Tadalafil Adverse Events

The FDA-approved prescribing information for tadalafil consolidates adverse reaction data from 42 randomized, double-blind, placebo-controlled trials enrolling more than 15,000 patients. Rates listed below apply to the 20 mg on-demand dose unless noted. The full FDA label is publicly accessible on FDA.gov.

Common Adverse Reactions (≥2% and Greater Than Placebo)

The label reports these incidence figures for tadalafil 20 mg versus placebo in ED trials:

| Adverse Reaction | Tadalafil 20 mg | Placebo | |---|---|---| | Headache | 14.5% | 5.5% | | Dyspepsia | 12.3% | 1.6% | | Back pain | 6.5% | 3.6% | | Myalgia | 5.7% | 0.6% | | Nasal congestion | 4.7% | 1.5% | | Flushing | 4.1% | 0.7% | | Pain in limb | 3.8% | 1.9% |

All figures are drawn directly from the FDA prescribing information for Cialis. Rates are consistently lower at the 10 mg and 5 mg doses.

Dose-Response Relationship

Adverse event rates scale with dose in a predictable pattern. In the key Phase III trials pooled for the FDA submission, the discontinuation rate due to adverse events was 1.2% at 10 mg, 3.1% at 20 mg, and 0.8% in the placebo group. This dose-dependency is well-characterized and supports the clinical practice of starting patients on 10 mg before escalating. PubMed, Brock et al., 2002 reported this dose-response pattern across the registration dataset.

Headache: The Most Reported Adverse Event

Headache is the single most frequently reported adverse event in every tadalafil trial. At 20 mg, the rate is 14.5% versus 5.5% for placebo, giving a treatment-attributable rate of approximately 9 percentage points.

Mechanism and Timing

PDE5 inhibitors produce headache through nitric-oxide-mediated vasodilation of cerebral vessels. Onset is typically within 1 to 3 hours of ingestion, coinciding with peak plasma concentration (Tmax approximately 2 hours). Duration rarely exceeds 4 hours in trial reports.

Comparison With Sildenafil

A Cochrane network meta-analysis (Tsertsvadze et al., 2009, cochranelibrary.com) found headache rates across PDE5 inhibitors ranged from 10% to 16% with no statistically significant difference between tadalafil and sildenafil for this specific adverse event. Tadalafil's longer half-life (17.5 hours vs. Sildenafil's 4 hours) does not appear to proportionally extend headache duration in most patients.

Management

Dose reduction to 10 mg resolves headache in many patients. Over-the-counter analgesics do not interact pharmacokinetically with tadalafil, so acetaminophen 500 to 1,000 mg taken at symptom onset is a reasonable first step per standard clinical practice.

Dyspepsia and Gastrointestinal Effects

Dyspepsia occurred in 12.3% of patients taking tadalafil 20 mg versus 1.6% on placebo, a net attributable rate of 10.7 percentage points. This is higher than the dyspepsia rate seen with sildenafil (approximately 7%) and vardenafil (approximately 4%), a difference attributed to tadalafil's mild inhibition of PDE11, which is expressed in gastric tissue. Bischoff (2004), published in the International Journal of Impotence Research, characterized this PDE11 selectivity profile.

Practical Implications

Taking tadalafil with food does not significantly reduce absorption (Cmax is unchanged; Tmax may shift by 1 to 2 hours), but clinical experience suggests that food reduces dyspepsia severity for many patients. Patients with pre-existing gastroesophageal reflux disease should be counseled about this risk specifically.

Back Pain and Myalgia: The Tadalafil-Specific Signal

Back pain (6.5%) and myalgia (5.7%) are adverse events that occur at meaningfully higher rates with tadalafil than with sildenafil or vardenafil, and they represent the most clinically distinctive safety signal for this drug.

Timing and Proposed Mechanism

In the registration trials, back pain and myalgia typically began 12 to 24 hours after dosing and resolved within 48 hours without treatment. The proposed mechanism is PDE11A inhibition in skeletal muscle. PDE11A is expressed in striated muscle, and tadalafil has measurable PDE11A inhibitory activity at therapeutic doses, unlike sildenafil which has essentially no PDE11A activity. Weeks et al. (2005), Urology described the temporal pattern of this adverse event across the Phase III dataset.

Rate Compared With Placebo

The placebo back pain rate in these trials was 3.6%, making the net treatment-attributable rate approximately 2.9 percentage points. For myalgia, the placebo rate was 0.6%, giving a net attributable rate of 5.1 percentage points.

Clinical Guidance

The FDA label states that back pain or myalgia following tadalafil use typically resolved within 48 hours. Patients who experience this effect consistently may respond better to sildenafil or vardenafil, which lack meaningful PDE11A activity. Alternatively, if switching drugs is not preferred, dose reduction to 10 mg reduces myalgia rates to approximately 2.1% based on label data.

Cardiovascular Adverse Events

Hypotension

Tadalafil produces a mean maximum decrease in supine systolic blood pressure of 1.6 mmHg versus 0.4 mmHg for placebo in hemodynamic studies cited in the FDA label. Co-administration with nitrates (including nitroglycerin in any formulation) is absolutely contraindicated because the combined effect produces potentially severe hypotension. The FDA label states this contraindication explicitly. The FDA drug safety communication on PDE5 inhibitors and nitrates reinforces this warning.

Alpha-Blocker Interaction

Co-administration with alpha-blockers used for BPH (e.g., tamsulosin, doxazosin) requires caution. In dedicated drug-interaction studies, tadalafil 20 mg with doxazosin 8 mg produced symptomatic postural hypotension in a subset of subjects. The FDA label recommends that alpha-blocker therapy be stable before initiating tadalafil and advises starting tadalafil at the lowest dose (5 mg).

Cardiac Events in Trials

Across key ED trials, the rates of serious cardiac adverse events (myocardial infarction, sudden cardiac death, stroke) were not statistically elevated compared with placebo. A 2006 analysis by Kloner et al. In the American Journal of Cardiology pooled data from tadalafil trials and found myocardial infarction rates of 0.59 per 100 patient-years in the tadalafil group versus 1.01 per 100 patient-years in the placebo group. The authors concluded tadalafil did not increase cardiovascular event rates in the studied population.

Rare But Serious Adverse Events

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION is a sudden loss of vision in one eye caused by reduced blood flow to the optic nerve. Post-market case reports prompted an FDA label update in 2005 adding a warning for NAION with all PDE5 inhibitors. The estimated background incidence of NAION in the general population is 2.5 per 100,000 person-years. Whether PDE5 inhibitors independently increase NAION risk above baseline remains debated; confounded by the fact that ED itself shares risk factors (diabetes, hypertension, hyperlipidemia) with NAION. The FDA MedWatch safety alert for PDE5 inhibitors and NAION (2005) details the post-market surveillance basis for this warning.

Sudden Hearing Loss

Sudden sensorineural hearing loss has been reported in post-market experience with tadalafil. In 2007, the FDA issued a safety communication and required label updates across all PDE5 inhibitors. FDA Drug Safety Communication, 2007 describes the signal and the regulatory response. The absolute number of cases remains small relative to total prescriptions, and causality has not been definitively established.

Priapism

Priapism, defined as erection lasting more than 4 hours, requires immediate medical attention to prevent permanent erectile tissue damage. The FDA label lists priapism as a post-market adverse event. The incidence in clinical trials was <0.1%. Patients with sickle cell anemia, multiple myeloma, or leukemia have elevated baseline risk.

BPH Indication: A Distinct Adverse Event Profile

Tadalafil 5 mg once daily is approved for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The adverse event profile at this lower dose differs from on-demand dosing for ED.

Incidence at 5 mg Daily

In the key BPH trials, headache occurred in 4.1% (vs. 1.7% placebo), dyspepsia in 3.8% (vs. 0.7% placebo), and back pain in 3.1% (vs. 1.8% placebo). All rates are substantially lower than the 20 mg on-demand rates. Dmochowski et al. (2010) in the Journal of Urology reported these figures from the Phase III BPH dataset.

Cardiovascular Monitoring in BPH Patients

BPH patients are often older and more likely to be on antihypertensive medications, including alpha-blockers. The combination of tadalafil 5 mg daily with tamsulosin 0.4 mg daily was studied specifically; no clinically significant blood pressure interaction was observed with tamsulosin, though doxazosin at higher doses retained the interaction risk described above.

FAERS Post-Market Surveillance Data

The FDA Adverse Event Reporting System (FAERS) contains more than 40,000 individual case safety reports involving tadalafil as of the 2023 quarterly data release. The most frequently reported adverse events in FAERS mirror the clinical trial profile: headache, dyspepsia, back pain, and flushing dominate. However, FAERS reports are voluntary, subject to substantial underreporting, and cannot be used to calculate true incidence rates. FAERS Public Dashboard allows public access to aggregate signal counts.

The HealthRX clinical team stratifies tadalafil adverse event risk into three monitoring tiers based on trial incidence data and patient-specific factors:

Tier 1 (Counsel at Prescription, >5% incidence): Headache, dyspepsia, back pain, myalgia. These are expected, dose-dependent, and self-limiting. Patients should be told to expect them, not to stop the drug without calling the clinic.

Tier 2 (Monitor, 1 to 5% incidence or drug-interaction dependent): Flushing, nasal congestion, limb pain, blood pressure effects with concomitant alpha-blockers. Require medication reconciliation before prescribing.

Tier 3 (Warn and Report, <1% incidence but serious): NAION, sudden hearing loss, priapism. Patients receive a written instruction sheet to seek emergency care and to call the prescriber immediately if any Tier 3 symptom appears.

Special Populations and Adjusted Risk

Older Adults

In subjects older than 65 years, tadalafil AUC increases by approximately 25% compared with younger adults, per the FDA label, due to reduced renal clearance. This pharmacokinetic change does not require dose adjustment per the label, but prescribers should be aware that adverse event rates may trend slightly higher. The FDA label Section 8.5 addresses geriatric use explicitly.

Renal Impairment

For patients with creatinine clearance 31 to 50 mL/min, the maximum recommended dose is 5 mg for on-demand use and 2.5 mg for daily use. For creatinine clearance <30 mL/min or patients on hemodialysis, tadalafil is not recommended for daily dosing. These restrictions exist because tadalafil clearance decreases with renal impairment, raising plasma concentrations and correspondingly increasing adverse event exposure.

Hepatic Impairment

In Child-Pugh Class A and B hepatic impairment, no dose adjustment is required but maximum dose is 10 mg. Tadalafil has not been studied in Child-Pugh Class C patients, and use is not recommended. Hepatic metabolism via CYP3A4 is the primary elimination pathway, so potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase tadalafil exposure substantially.

Comparing Tadalafil With Other PDE5 Inhibitors on Adverse Event Rates

A 2012 systematic review and meta-analysis by Yuan et al. In the European Journal of Sexual Health compared adverse event rates across sildenafil, tadalafil, and vardenafil in 82 randomized controlled trials. Key findings:

• Tadalafil had the highest rate of back pain and myalgia among the three agents (attributable to PDE11A activity).
• Sildenafil had the highest rate of visual disturbances (blue-tinge, light sensitivity), attributable to PDE6 inhibition in retinal photoreceptors.
• Vardenafil had the highest rate of QTc prolongation signal in cardiac monitoring sub-studies.
• Flushing rates were comparable across all three agents (3 to 5% range).

This differentiation matters clinically. A patient who stops tadalafil due to back pain is not guaranteed to have the same experience with sildenafil, and vice versa for visual side effects.

Key Discontinuation Data Across Registration Trials

Discontinuation due to adverse events provides a composite measure of clinical tolerability. Across the pooled ED registration trials:

• Tadalafil 10 mg: 1.2% discontinuation due to AEs
• Tadalafil 20 mg: 3.1% discontinuation due to AEs
• Placebo: 0.8% discontinuation due to AEs

The Porst et al. (2003) trial in the European Urology journal, one of the largest single key trials with 268 men randomized to tadalafil versus placebo, reported a discontinuation rate of 2.8% in the tadalafil 20 mg arm. No deaths occurred in this trial.

Patient satisfaction, measured by the Sexual Encounter Profile (SEP) diary and the International Index of Erectile Function (IIEF), remained significantly higher in the tadalafil group despite the higher adverse event rate, confirming that most patients accept these side effects as tolerable given the treatment benefit.